The analgesics market would grow at a CAGR of 3.9% over the predicted time frame. The market is expected to increase in value from US$ 109.93 Bn in 2022 to US$ 149.3 Bn in 2030.
Key Takeaways:
- North America region has accounted 42.3% revenue share in 2021.
- Asia Pacific region is expected to grow at a CAGR of 7.8% from 2022 to 2030.
- By drug type, the NSAID’s segment is expected to reach at a CAGR of 4.5% from 2022 to 2030.
- By indication, the surgical pain has held revenue share of over 53.5% in 2021. However, the intravenous segment is expected to grow at a CAGR of 7.7% from 2022 to 2030
- By type, prescription segment has accounted 71% revenue share in 2021.
- By route of administration, the oral segment has 48% revenue share in 2021.
The on analgesics Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2282
A recent report provides crucial insights along with application based and forecast information in the Global Analgesics Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Analgesics market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Analgesics market are included as given below:
Analgesics Market Key Players are: Abbott, Pfizer Inc., Eli Lilly & Company, Endo International plc, F. Hoffmann-La Roche AG Bausch Health Companies Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Johnson & Johnson Private Limited, GSK plc., Purdue Pharma L.P.
Market Segments
By Drug Class
- Opioids
- Morphine
- Fentanyl
- Codiene
- Methadone
- Meperidine
- Oxycodone
- Tramadol
- Dextromethorphan
- Buprenorphine
- Others
- NSAIDs
- Local Anesthetics
- Acetaminophen
By Indication
- Surgical Pain
- Cancer Pain
- Neuropathic Pain
- Others
By Type
- Prescription
- OTC
By Pain Type
- Musculoskeletal Pain
- Surgical and Trauma Pain
- Cancer Pain
- Neuropathic Pain
- Migraine
- Obstetrical Pain
- Fibromyalgia
- Pain due to Burns
- Dental/Facial Pain
- Paediatric Pain
- Others
By Application
- Internal Analgesics
- External Analgesics
By Route of Administration
- Oral
- Parenteral
- Transdermal
- Others
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Drug Stores
- Online pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global analgesics market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the analgesics market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Analgesics Market, By Drug Class
7.1. Analgesics Market, by Drug Class, 2022-2030
7.1.1. Opioids
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. NSAIDs
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Local Anesthetics
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Acetaminophen
7.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Analgesics Market, By Indication
8.1. Analgesics Market, by Indication, 2022-2030
8.1.1. Surgical Pain
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Cancer Pain
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Neuropathic Pain
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Analgesics Market, By Type
9.1. Analgesics Market, by Type, 2022-2030
9.1.1. Prescription
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. OTC
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Analgesics Market, By Pain Type
10.1. Analgesics Market, by Pain Type, 2022-2030
10.1.1. Musculoskeletal Pain
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Surgical and Trauma Pain
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Cancer Pain
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Neuropathic Pain
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Migraine
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Obstetrical Pain
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7. Fibromyalgia
10.1.7.1. Market Revenue and Forecast (2017-2030)
10.1.8. Pain due to Burns
10.1.8.1. Market Revenue and Forecast (2017-2030)
10.1.9. Dental/Facial Pain
10.1.9.1. Market Revenue and Forecast (2017-2030)
10.1.10. Paediatric Pain
10.1.10.1. Market Revenue and Forecast (2017-2030)
10.1.11. Others
10.1.11.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Analgesics Market, By Application
11.1. Analgesics Market, by Application, 2022-2030
11.1.1. Internal Analgesics
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. External Analgesics
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Analgesics Market, By Route of Administration
12.1. Analgesics Market, by Route of Administration, 2022-2030
12.1.1. Oral
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Oral
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Transdermal
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. Others
12.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Analgesics Market, By Distribution Channel
13.1. Analgesics Market, by Distribution Channel, 2022-2030
13.1.1. Hospital pharmacies
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Retail pharmacies
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Drug Stores
13.1.3.1. Market Revenue and Forecast (2017-2030)
13.1.4. Online pharmacies
13.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Analgesics Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.1.2. Market Revenue and Forecast, by Indication (2017-2030)
14.1.3. Market Revenue and Forecast, by Type (2017-2030)
14.1.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.1.5. Market Revenue and Forecast, by Application (2017-2030)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.1.8.2. Market Revenue and Forecast, by Indication (2017-2030)
14.1.8.3. Market Revenue and Forecast, by Type (2017-2030)
14.1.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.1.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Indication (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Type (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.1.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.2. Market Revenue and Forecast, by Indication (2017-2030)
14.2.3. Market Revenue and Forecast, by Type (2017-2030)
14.2.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.2.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Indication (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Type (2017-2030)
14.2.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.2.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.9.2. Market Revenue and Forecast, by Indication (2017-2030)
14.2.9.3. Market Revenue and Forecast, by Type (2017-2030)
14.2.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.2.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.10.2. Market Revenue and Forecast, by Indication (2017-2030)
14.2.10.3. Market Revenue and Forecast, by Type (2017-2030)
14.2.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.2.10.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Indication (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Type (2017-2030)
14.2.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.2.11.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.2. Market Revenue and Forecast, by Indication (2017-2030)
14.3.3. Market Revenue and Forecast, by Type (2017-2030)
14.3.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.3.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)
14.3.8.3. Market Revenue and Forecast, by Type (2017-2030)
14.3.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.3.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.9.2. Market Revenue and Forecast, by Indication (2017-2030)
14.3.9.3. Market Revenue and Forecast, by Type (2017-2030)
14.3.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.3.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Indication (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Type (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.3.10.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.11.2. Market Revenue and Forecast, by Indication (2017-2030)
14.3.11.3. Market Revenue and Forecast, by Type (2017-2030)
14.3.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.3.11.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.2. Market Revenue and Forecast, by Indication (2017-2030)
14.4.3. Market Revenue and Forecast, by Type (2017-2030)
14.4.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.4.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)
14.4.8.3. Market Revenue and Forecast, by Type (2017-2030)
14.4.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.4.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.9.2. Market Revenue and Forecast, by Indication (2017-2030)
14.4.9.3. Market Revenue and Forecast, by Type (2017-2030)
14.4.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.4.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Indication (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Type (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.4.10.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.11.2. Market Revenue and Forecast, by Indication (2017-2030)
14.4.11.3. Market Revenue and Forecast, by Type (2017-2030)
14.4.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.4.11.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.5.2. Market Revenue and Forecast, by Indication (2017-2030)
14.5.3. Market Revenue and Forecast, by Type (2017-2030)
14.5.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.5.5. Market Revenue and Forecast, by Application (2017-2030)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.5.8.2. Market Revenue and Forecast, by Indication (2017-2030)
14.5.8.3. Market Revenue and Forecast, by Type (2017-2030)
14.5.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.5.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Indication (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Type (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
Chapter 15. Company Profiles
15.1. Abbott
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Pfizer Inc.
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Eli Lilly & Company
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Endo International plc
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. F. Hoffmann-La Roche AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Bausch Health Companies Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Merck & Co. Inc.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. AbbVie Inc.
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Novartis AG
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Johnson & Johnson Private Limited
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments